Record Number of Bendamustine Abstracts Accepted for Presentation at the Annual Meeting of the American Society of Hematology (ASH)

Record Number of Bendamustine Abstracts Accepted for Presentation at the Annual Meeting of the American Society of Hematology (ASH) PR Newswire CAMBRIDGE, England, December 3, 2012 CAMBRIDGE, England, December 3, 2012 /PRNewswire/ -- Total of 43 bendamustine abstracts to be presented at ASH, including five oral presentations New data supports use of bendamustine-rituximab (B-R) regimen in indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) 43 abstracts, announcing the results of studies involving bendamustine in a number of lymphoid malignancies, including thchronic lymphocytic leukemia (CLL), multiple myeloma (MM), indolent NHL and MCL, will be presented at the 54 Annual Meeting of the American Society of Hematology (ASH), taking place from 8-11 December 2012 in Atlanta, Georgia. Five will be oral presentations. Two oral and three poster presentations focus on indolent NHL (iNHL) and MCL, comparing treatment with bendamustine-rituximab (B-R) to the standard first-line treatment, CHOP-R/CVP-R. One study demonstrated improved complete response rates and progression free survival (PFS) vs. CHOP-R, whilst another study demonstrated improved quality of life with B-R compared to the current standards of care (CHOP-R/CVP-R) for patients with iNHL or [1] [2] [3]MCL. , , "We are delighted that such a wealth of bendamustine data has been included in the ASH scientific program," said Antony Mattessich, Regional Director, Europe, at Mundipharma.